https://biotechmorning.com/news/fda-rejects-replimune-melanoma-drug-twice-2 Biotech Morning en 2026-04-19T14:06:45.145Z The FDA Said No. Twice. Now Replimune Is Fighting for Survival. https://biotechmorning.com/news/foundayo-oral-obesity-pill-launch-prescriptions Biotech Morning en 2026-04-19T14:06:02.299Z The Obesity Pill That Just Changed the Game https://biotechmorning.com/news/fda-reclassifies-banned-peptides-compounding-pharmacies Biotech Morning en 2026-04-19T14:05:16.824Z The FDA Just Made 12 Banned Peptides Legal Again https://biotechmorning.com/news/janux-double-masked-t-cell-engager Biotech Morning en 2026-04-18T14:08:57.191Z The Cancer Drug Designed to Ignore Everything Except the Tumor https://biotechmorning.com/news/ucb-neurona-epilepsy-cell-therapy-acquisition Biotech Morning en 2026-04-18T14:08:13.557Z UCB Just Dropped $1.15 Billion on a Brain Cell Transplant for Epilepsy https://biotechmorning.com/news/cerebras-2-billion-ipo-bet-against-nvidia Biotech Morning en 2026-04-18T14:07:27.377Z The Bet Against Nvidia's AI Monopoly https://biotechmorning.com/news/roivant-ceo-china-biotech-red-herring Biotech Morning en 2026-04-18T14:06:47.986Z Roivant's CEO Says We're All Worried About the Wrong Thing https://biotechmorning.com/news/merck-secret-weapon-life-after-keytruda Biotech Morning en 2026-04-18T14:06:10.714Z Merck's Secret Weapon for Life After Keytruda https://biotechmorning.com/news/openai-gpt-rosalind-biotech-drug-discovery Biotech Morning en 2026-04-18T14:05:27.589Z OpenAI Just Built an AI That Speaks Fluent Biology